Literature DB >> 15356114

CD59a is the primary regulator of membrane attack complex assembly in the mouse.

Sivasankar Baalasubramanian1, Claire L Harris, Rossen M Donev, Masashi Mizuno, Nader Omidvar, Wen-Chao Song, B Paul Morgan.   

Abstract

Gene-deleted mice have provided a potent tool in efforts to understand the roles of complement and complement-regulating proteins in vivo. In particular, mice deficient in the membrane regulators complement receptor 1-related gene/protein y, decay-accelerating factor, or CD59 have demonstrated homeostatic relevance and backcrossing between the strains has revealed cooperativity in regulation. In mouse, genes encoding decay-accelerating factor and CD59 have been duplicated and show differential expression in tissues, complicating interpretation and extrapolation of findings to man. The first described form of CD59, CD59a, is broadly distributed and deletion of the cd59a gene causes a mild hemolytic phenotype with increased susceptibility in complement-mediated disease models. The distribution of the second form, CD59b, was originally described as testis specific, but later by some as widespread. Deletion of the cd59b gene caused a severe hemolytic and thrombotic phenotype. To apply data from these mouse models to man it is essential to know the relative distribution and functional roles of these two forms of CD59. We have generated new specific reagents and used them in sensitive quantitative analyses to comprehensively characterize expression of mRNA and protein and functional roles of CD59a and CD59b in wild-type (wt) and CD59a-negative mice. cd59b mRNA was detected only in testis and, at very low levels, in bone marrow. CD59b protein was present on mature spermatozoa and precursors and, in trace amounts, erythrocytes. Erythrocyte CD59b did not inhibit complement lysis except when CD59a was absent or blocked. These data confirm that CD59a is the primary regulator of complement membrane attack in mouse. Copyright 2004 The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356114     DOI: 10.4049/jimmunol.173.6.3684

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice.

Authors:  Fengming Liu; Lin Wu; Gongxiong Wu; Chun Wang; Lining Zhang; Stephen Tomlinson; Xuebin Qin
Journal:  Atherosclerosis       Date:  2014-03-15       Impact factor: 5.162

2.  The protective role of CD59 and pathogenic role of complement in hepatic ischemia and reperfusion injury.

Authors:  Jinyan Zhang; Weiguo Hu; Wei Xing; Tao You; Junming Xu; Xuebin Qin; Zhihai Peng
Journal:  Am J Pathol       Date:  2011-10-19       Impact factor: 4.307

3.  Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner.

Authors:  M Paula Longhi; Baalasubramanian Sivasankar; Nader Omidvar; B Paul Morgan; Awen Gallimore
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 4.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

Review 5.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

6.  Generation and phenotyping of mCd59a and mCd59b double-knockout mice.

Authors:  Xuebin Qin; Weiguo Hu; Wenping Song; Luciano Grubissich; Xuemei Hu; Gongxiong Wu; Sean Ferris; Martin Dobarro; Jose A Halperin
Journal:  Am J Hematol       Date:  2009-02       Impact factor: 10.047

7.  Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice.

Authors:  Denise Harhausen; Uldus Khojasteh; Philip F Stahel; B Paul Morgan; Wilfried Nietfeld; Ulrich Dirnagl; George Trendelenburg
Journal:  J Neuroinflammation       Date:  2010-03-04       Impact factor: 8.322

8.  CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?

Authors:  Baalasubramanian Sivasankar; M Paula Longhi; Kathleen M E Gallagher; Gareth J Betts; B Paul Morgan; Andrew J Godkin; Awen M Gallimore
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

9.  Cell surface complement regulators moderate experimental myasthenia gravis pathology.

Authors:  Linda L Kusner; Jose A Halperin; Henry J Kaminski
Journal:  Muscle Nerve       Date:  2012-10-05       Impact factor: 3.217

10.  The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice.

Authors:  Ruth D Lewis; Christopher L Jackson; B Paul Morgan; Timothy R Hughes
Journal:  Mol Immunol       Date:  2009-12-02       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.